|
|
| Line 6: |
Line 6: |
| == Structural highlights == | | == Structural highlights == |
|
| |
|
| All cyclins have an all-α helix fold and share an identical ca. 100 residue domain called 'cyclin box' which binds CDK. Two 5 α-helix cyclin boxes are shown. | | All cyclins have an all-α helix fold and share an identical ca. 100 residue domain called 'cyclin box' which binds CDK. Two 5 α-helix cyclin boxes are shown.<ref>PMID:09433129</ref> |
|
| |
|
| </StructureSection> | | </StructureSection> |
Revision as of 10:15, 16 December 2015
| Function
Cyclin (CYC) activates CYC-dependent kinase (CDK) thus acting in the control of the cell cycle. The CYC name derives from the fact that different CYCs are expressed during different phases of the cell cycle. Among the CYCs, CYCA is active in the S phase, CYCD regulate the transition from G1 to S.[1] See also Intrinsically Disordered Protein.
Structural highlights
All cyclins have an all-α helix fold and share an identical ca. 100 residue domain called 'cyclin box' which binds CDK. Two 5 α-helix cyclin boxes are shown.[2]
- ↑ Galderisi U, Jori FP, Giordano A. Cell cycle regulation and neural differentiation. Oncogene. 2003 Aug 11;22(33):5208-19. PMID:12910258 doi:https://dx.doi.org/10.1038/sj.onc.1206558
- ↑ Noble ME, Endicott JA, Brown NR, Johnson LN. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem Sci. 1997 Dec;22(12):482-7. PMID:9433129
|
3D Structures of Cyclin
Updated on 16-December-2015
{"openlevels":0}
- CYCA2
- Intrinsically Disordered Protein, 2wpa, 2wxv, 2wih, 2wip, 3f5x, 3eoc, 3eid, 3ej1, 3dog, 3ddp, 3ddq, 3bht, 2v22, 2uue, 2i40, 2bkz, 2c5n, 2c5o, 2c5v, 2c5x, 2c5y, 2bpm, 2c4g, 1fvv, 2c6t – hCYCA2 +CDK2+inhibitor - human
- 3bhu, 3bhv, 2uzd, 2uzb, 2uze, 2uzl, 2uzn, 2uzo, 2iw6, 2iw8, 2iw9, 2g9x, 1oi9, 1oiu, 1oiy, 1ogu, 1p5e, 1pkd, 1h1p, 1h1q, 1h1r, 1h1s, 4cfx, 4cfv, 4cfu, 4cfm - hCYCA2 +CDK2 T160P+inhibitor
- 1fin - hCYCA2 +CDK2
- 1vyw - hCYCA2 C-terminal + hCDK2
- 1jst, 3tnw - hCYCA2 +CDK2 T160P
- 1h24, 1h25, 1h26, 1h27, 1h28, 1gy3 - hCYCA2 +CDK2 T160P+peptide
- 4bck, 4bcm, 4bcn, 4bco, 4bcp, 4bcq, 4cfn, 4cfw - hCYCA2 +CDK2 T160P + inhibitor
- 4fx3 - hCYCA2 +CDK2 + inhibitor
- 4eoi, 4eoj, 4eok, 4eol, 4eom, 4eon, 4eoo, 4eop, 4eoq, 4eor, 4eos - hCYCA2 C-terminal +CDK2 T160P + inhibitor
- 2cjm - hCYCA2 +CDK2 T160P Y15P
- 2cch - hCYCA2 +CDK2 T160P+ATP analog
- 4i3z, 4ii5 - hCYCA2 +CDK2 T160P+ADP + Mg
- 2cci - hCYCA2 +CDK2 T160P+CDC homolog
- 2wma, 2wmb, 2x1n, 2wev, 2wfy, 2whb, 1okv, 1okw, 1ol1, 1ol2, 1urc, 1qmz, 3qhw - hCYCA2 +CDK2+peptide
- 1jsu - hCYCA2 +CDK2 (mutant)+P27
- 3qhr, 3khw - CYCA2 + P33 protein kinase + CDK2 peptide – mouse
- CYCA3
- 1vin – CYCA3 - bovine
- 1e9h – hCYCA3 +CDK2 T160P+inhibitor
- CYCB1
- 2b9r – hCYCB1 (mutant)
- 2jgz - hCYCB1 +CDK2
- CYCC
- CYCD
- CYCE
- 1w98 – hCYCE1 +CDK2 T160P
- CYCH
- CYCK
- 2i53 – hCYCK N-terminal
- 4un0 - hCYCK + CDK12 T160P
- 4cxa - hCYCK + CDK12 T160P + AMPPNP
- 4cjy - hCYCK +CDK12 T160P+inhibitor
- CYCT
- 3blh - hCYCT1 +CDK9
- 3blq - hCYCT1 +CDK9+ATP
- 4imy - hCYCT1 +CDK9 TPO160 +AMP + AF4/MRF2 family member 4
- 3lq5, 3tn8, 3tnh, 3tni, 4bcf, 4bcg, 4bch, 4bci, 4bcj – hCYCT1 (mutant)+CDK9
- 3blr - hCYCT1 +CDK9+inhibitor
- 3my1, 4ec8, 4ec9 - hCYCT1 (mutant)+CDK9 TPO160 +inhibitor
- 3mi9, 3mia - hCYCT1 +CDK9+protein TAT
- 2w2h - CYCT1 +protein TAT + RNA – horse
- 2ivx – hCYCT2 (mutant)
- CYC
- 2pk9 – yCYC PHO80 +CDK PHO85 – yeast
- 2pmi - yCYC PHO80 +CDK PHO85+ATPgS
- Viral CYC
- 2euf, 2f2c, 2xo2, 1jow – V-CYC viral+hCDK6 – Herpesvirus
- 1bu2 – V-CYC
- 1xo2 - V-CYC + hCDK6 + inhibitor
- 1g3n - V-CYC viral+hCDK6+CDK6 inhibitor
- 1f5q - V-CYC g viral+hCDK2
References
